Nothing Special   »   [go: up one dir, main page]

BR112021017525A2 - Solid Capsid Assembly Modulator Formulation - Google Patents

Solid Capsid Assembly Modulator Formulation

Info

Publication number
BR112021017525A2
BR112021017525A2 BR112021017525A BR112021017525A BR112021017525A2 BR 112021017525 A2 BR112021017525 A2 BR 112021017525A2 BR 112021017525 A BR112021017525 A BR 112021017525A BR 112021017525 A BR112021017525 A BR 112021017525A BR 112021017525 A2 BR112021017525 A2 BR 112021017525A2
Authority
BR
Brazil
Prior art keywords
solid
capsid assembly
assembly modulator
modulator formulation
formulation
Prior art date
Application number
BR112021017525A
Other languages
Portuguese (pt)
Inventor
Abhishek Singh
Elisabeth Balmain Claire
Josiane W Verstraete Dominique
Anne R VAN DYCKE Frederic
Jan Snoeys
Jozef Vandenbossche Joris
Maria Jansens
Bertil S ANNÉ Michaël
Oliver Lenz
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB2019/000231 external-priority patent/WO2019175657A1/en
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of BR112021017525A2 publication Critical patent/BR112021017525A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

formulação sólida de modulador de montagem de capsídeo. a presente invenção refere-se às formas de dosagem orais sólidas de um inibidor de montagem de capsídeo para o tratamento de infecção por vírus da hepatite b.solid formulation of capsid assembly modulator. The present invention relates to solid oral dosage forms of a capsid assembly inhibitor for the treatment of hepatitis B virus infection.

BR112021017525A 2019-03-13 2020-03-13 Solid Capsid Assembly Modulator Formulation BR112021017525A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/IB2019/000231 WO2019175657A1 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
US16/352,754 US10973801B2 (en) 2018-03-14 2019-03-13 Capsid assembly modulator dosing regimen
EP2019056348 2019-03-13
EP19197566 2019-09-16
PCT/EP2020/056991 WO2020183020A1 (en) 2019-03-13 2020-03-13 Capsid assembly modulator solid formulation

Publications (1)

Publication Number Publication Date
BR112021017525A2 true BR112021017525A2 (en) 2021-11-23

Family

ID=72427202

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017525A BR112021017525A2 (en) 2019-03-13 2020-03-13 Solid Capsid Assembly Modulator Formulation

Country Status (16)

Country Link
EP (1) EP3937928A1 (en)
JP (1) JP2022524819A (en)
KR (1) KR20210137484A (en)
CN (1) CN113557016A (en)
AU (1) AU2020235442A1 (en)
BR (1) BR112021017525A2 (en)
CA (1) CA3132095A1 (en)
CR (1) CR20210481A (en)
EC (1) ECSP21067052A (en)
IL (1) IL286209A (en)
JO (1) JOP20210250A1 (en)
MA (1) MA55280A (en)
MX (1) MX2021011030A (en)
PE (1) PE20212107A1 (en)
SG (1) SG11202109710QA (en)
WO (1) WO2020183020A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202011827YA (en) 2016-04-15 2021-01-28 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
JP2021515769A (en) * 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Capsid aggregation regulator dosing regimen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP2021515769A (en) * 2018-03-14 2021-06-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー Capsid aggregation regulator dosing regimen

Also Published As

Publication number Publication date
JOP20210250A1 (en) 2023-01-30
EP3937928A1 (en) 2022-01-19
AU2020235442A1 (en) 2021-08-12
PE20212107A1 (en) 2021-11-04
MX2021011030A (en) 2021-10-13
SG11202109710QA (en) 2021-10-28
ECSP21067052A (en) 2021-11-18
CN113557016A (en) 2021-10-26
WO2020183020A1 (en) 2020-09-17
KR20210137484A (en) 2021-11-17
JP2022524819A (en) 2022-05-10
CR20210481A (en) 2021-10-25
MA55280A (en) 2022-01-19
CA3132095A1 (en) 2020-09-17
IL286209A (en) 2021-10-31

Similar Documents

Publication Publication Date Title
CL2017001798A1 (en) Pyrazine compounds for the treatment of infectious diseases.
PH12020552127A1 (en) Hepatitis b capsid assembly modulators
BR112018071678A2 (en) therapeutic compounds useful for the prophylactic or therapeutic treatment of an HIV virus infection
CR20150454A (en) AMIDA COMPOUNDS FOR HIV TREATMENT
BR112022000503A2 (en) Compounds Useful for Treating Influenza Virus Infections
BR112022012594A2 (en) DOSAGE OF GAMMA-HYDROXYBUTYRATE (GHB)
BR112018009009A8 (en) combined therapy of an hbv capsid formation inhibitor and an interferon
BR112018071048A2 (en) combinations and methods comprising a capsid assembly inhibitor
CL2021000227A1 (en) Dosage regimen of the capsid assembly modulator. (application divisional 2254-2020)
CL2021001212A1 (en) Stabilized vrs prefusion f proteins.
BR112023020781A2 (en) CBL-B MODULATORS AND USES THEREOF
CO2024006742A2 (en) Therapeutic compounds for HIV virus infection
BR112021017525A2 (en) Solid Capsid Assembly Modulator Formulation
MX2017015462A (en) Attenuated influenza vectors for the prevention and/or treatment of infectious diseases and for the treatment of oncological diseases.
CL2021002307A1 (en) Use of oncolytic viruses for cancer treatment
SA520420046B1 (en) Fused tricyclic pyridazinone compounds and prodrugs thereof useful to treat orthomyxovirus infections
CR20110542A (en) Compounds and Methods for Viral Treatment
CL2015003752A1 (en) Viral replication inhibitors, their preparation process and their therapeutic use
BR112017015597A2 (en) a3 adenosine receptor modulators
BR112022022263A2 (en) TREATMENT OF VIRAL INFECTIONS
BR112022009421A2 (en) DOSAGE SCHEMES FOR VACCINES
UY37166A (en) NUCLEOSID ALKYLIN ANALOGS AS INHIBITORS OF HUMAN RINOVIRUS
DK4021505T3 (en) DRUG FOR THE TREATMENT OF INFECTIOUS DISEASES
BR112022002459A2 (en) Process for the preparation of 2-chloro-1-(2-chlorothiazol-5-yl)ethanone
BR112021021060A2 (en) Anti-cd38 antibodies and formulations

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 3A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2734 DE 30-05-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.